This newly identified SIRT1-activating property of SIL may have enormous therapeutic implications and benefits in reducing not only the myocardial I-R injury, but also other types of cardiovascular disorders related to aging and metabolic dysregulation such as Type 2 diabetes. This evidence concerns the gene SIRT1 and cardiovascular disorder.